FDA's Peter Marks resigns, says he won't accept Kennedy's 'misinformation and lies'

Drew Armstrong

Executive Editor

Peter Marks, the head of the FDA’s Center for Biologics Evaluation and Research and one of the agency’s highest-profile officials, has suddenly resigned amid a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA's Peter Marks resigns, says he won't accept Kennedy's 'misinformation and lies'

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Isomorphic Labs gets $600M from Thrive, GV and Alphabet

Vertex’s second-generation diabetes cell therapy fails early-stage study

Bluebird gets new M&A bid, seeking to top private equity offer

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

BiomX’s phage therapy succeeds in Phase 2 diabetic bone infection study

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

FDA's Pe­ter Marks re­signs, says he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Executive Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

FDA's Peter Marks resigns, says he won't accept Kennedy's 'misinformation and lies'